| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 37 | 2025 | 979 | 4.960 |
Why?
|
| Antihypertensive Agents | 27 | 2025 | 363 | 3.900 |
Why?
|
| Blood Pressure | 32 | 2026 | 861 | 2.830 |
Why?
|
| Blood Pressure Determination | 9 | 2020 | 106 | 1.740 |
Why?
|
| Cardiovascular Diseases | 17 | 2025 | 1158 | 1.680 |
Why?
|
| Dementia | 12 | 2025 | 246 | 1.680 |
Why?
|
| Aged | 61 | 2025 | 10260 | 1.490 |
Why?
|
| Humans | 119 | 2026 | 32274 | 1.460 |
Why?
|
| Frail Elderly | 4 | 2025 | 69 | 1.250 |
Why?
|
| Electronic Health Records | 7 | 2025 | 179 | 1.240 |
Why?
|
| Female | 86 | 2026 | 19942 | 1.220 |
Why?
|
| Male | 79 | 2026 | 19437 | 1.140 |
Why?
|
| Obesity | 15 | 2026 | 1111 | 1.030 |
Why?
|
| Renal Insufficiency, Chronic | 8 | 2025 | 293 | 0.970 |
Why?
|
| Medicare | 5 | 2025 | 219 | 0.970 |
Why?
|
| Subacute Care | 1 | 2025 | 18 | 0.910 |
Why?
|
| Health Status | 6 | 2017 | 355 | 0.890 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 167 | 0.890 |
Why?
|
| Anemia, Sickle Cell | 6 | 2010 | 42 | 0.880 |
Why?
|
| Middle Aged | 49 | 2026 | 11848 | 0.880 |
Why?
|
| Patient Readmission | 1 | 2025 | 135 | 0.840 |
Why?
|
| Aged, 80 and over | 21 | 2025 | 3898 | 0.840 |
Why?
|
| Patient Discharge | 1 | 2025 | 204 | 0.830 |
Why?
|
| Psychotic Disorders | 1 | 2024 | 8 | 0.830 |
Why?
|
| Anthrax Vaccines | 3 | 2013 | 3 | 0.810 |
Why?
|
| Antibody Formation | 4 | 2013 | 47 | 0.800 |
Why?
|
| Nursing Homes | 1 | 2023 | 33 | 0.770 |
Why?
|
| United States | 24 | 2025 | 4072 | 0.770 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2026 | 541 | 0.740 |
Why?
|
| Genome-Wide Association Study | 11 | 2015 | 543 | 0.740 |
Why?
|
| Severity of Illness Index | 6 | 2025 | 853 | 0.730 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2023 | 1437 | 0.720 |
Why?
|
| Myocardial Infarction | 5 | 2023 | 465 | 0.660 |
Why?
|
| Polymorphism, Single Nucleotide | 16 | 2017 | 1050 | 0.650 |
Why?
|
| Life Style | 7 | 2023 | 393 | 0.640 |
Why?
|
| Risk Factors | 20 | 2024 | 3934 | 0.630 |
Why?
|
| Ethnic Groups | 7 | 2017 | 450 | 0.600 |
Why?
|
| Mobility Limitation | 2 | 2017 | 208 | 0.590 |
Why?
|
| Adult | 29 | 2026 | 9256 | 0.560 |
Why?
|
| Wet Macular Degeneration | 1 | 2017 | 3 | 0.540 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 158 | 0.540 |
Why?
|
| Quality of Life | 5 | 2010 | 964 | 0.530 |
Why?
|
| Visual Acuity | 1 | 2017 | 76 | 0.510 |
Why?
|
| Accidental Falls | 3 | 2025 | 104 | 0.470 |
Why?
|
| Acoustic Stimulation | 2 | 2015 | 121 | 0.470 |
Why?
|
| Dental Health Services | 2 | 2012 | 8 | 0.450 |
Why?
|
| Health Services Accessibility | 4 | 2010 | 242 | 0.440 |
Why?
|
| Emergency Service, Hospital | 4 | 2020 | 444 | 0.440 |
Why?
|
| Hot Flashes | 1 | 2015 | 49 | 0.440 |
Why?
|
| Electric Stimulation | 1 | 2015 | 135 | 0.440 |
Why?
|
| Neural Pathways | 1 | 2015 | 112 | 0.440 |
Why?
|
| Cohort Studies | 11 | 2024 | 1840 | 0.420 |
Why?
|
| Models, Genetic | 3 | 2012 | 93 | 0.410 |
Why?
|
| Age Factors | 9 | 2025 | 1179 | 0.410 |
Why?
|
| Overweight | 5 | 2026 | 252 | 0.410 |
Why?
|
| Glomerular Filtration Rate | 6 | 2021 | 302 | 0.400 |
Why?
|
| Fluorides, Topical | 2 | 2010 | 6 | 0.390 |
Why?
|
| Stomatognathic Diseases | 1 | 2012 | 4 | 0.380 |
Why?
|
| Genes, MHC Class II | 1 | 2012 | 4 | 0.370 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 4 | 2020 | 30 | 0.370 |
Why?
|
| Retrospective Studies | 9 | 2025 | 3624 | 0.360 |
Why?
|
| Uncertainty | 1 | 2012 | 11 | 0.360 |
Why?
|
| Myocardial Contraction | 2 | 2009 | 59 | 0.360 |
Why?
|
| Body Mass Index | 10 | 2026 | 863 | 0.340 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 89 | 0.340 |
Why?
|
| HLA-DQ Antigens | 1 | 2011 | 8 | 0.340 |
Why?
|
| HLA-DR Antigens | 1 | 2011 | 7 | 0.340 |
Why?
|
| Longitudinal Studies | 7 | 2025 | 757 | 0.340 |
Why?
|
| Child, Preschool | 13 | 2013 | 1233 | 0.330 |
Why?
|
| Proxy | 1 | 2010 | 8 | 0.330 |
Why?
|
| Bayes Theorem | 2 | 2011 | 82 | 0.320 |
Why?
|
| Cognition | 5 | 2023 | 547 | 0.320 |
Why?
|
| Child | 16 | 2013 | 2434 | 0.310 |
Why?
|
| Silene | 1 | 2009 | 1 | 0.310 |
Why?
|
| Flowers | 1 | 2009 | 2 | 0.310 |
Why?
|
| Selection, Genetic | 1 | 2009 | 7 | 0.310 |
Why?
|
| Parents | 2 | 2010 | 151 | 0.310 |
Why?
|
| Mental Health | 1 | 2010 | 111 | 0.310 |
Why?
|
| Geriatric Assessment | 2 | 2025 | 335 | 0.300 |
Why?
|
| Follow-Up Studies | 11 | 2025 | 2240 | 0.300 |
Why?
|
| Anti-Obesity Agents | 2 | 2026 | 9 | 0.300 |
Why?
|
| Phentermine | 2 | 2026 | 9 | 0.290 |
Why?
|
| Prevalence | 4 | 2022 | 955 | 0.290 |
Why?
|
| Psychometrics | 1 | 2009 | 137 | 0.280 |
Why?
|
| Adolescent | 18 | 2015 | 3517 | 0.280 |
Why?
|
| Residence Characteristics | 1 | 2010 | 178 | 0.280 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 427 | 0.280 |
Why?
|
| Risk Assessment | 4 | 2024 | 1425 | 0.280 |
Why?
|
| Behavior Therapy | 2 | 2020 | 102 | 0.280 |
Why?
|
| Acute Coronary Syndrome | 2 | 2023 | 167 | 0.270 |
Why?
|
| African Americans | 8 | 2019 | 1335 | 0.270 |
Why?
|
| Ventricular Function, Left | 1 | 2009 | 264 | 0.270 |
Why?
|
| Weight Loss | 5 | 2026 | 410 | 0.270 |
Why?
|
| Wisconsin | 7 | 2012 | 21 | 0.270 |
Why?
|
| Stroke | 2 | 2023 | 691 | 0.260 |
Why?
|
| Medicaid | 4 | 2011 | 101 | 0.240 |
Why?
|
| Creatinine | 3 | 2022 | 191 | 0.240 |
Why?
|
| Treatment Outcome | 8 | 2025 | 3416 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2025 | 1223 | 0.240 |
Why?
|
| Haplotypes | 5 | 2015 | 213 | 0.240 |
Why?
|
| Neoplasms | 2 | 2025 | 754 | 0.240 |
Why?
|
| Systole | 3 | 2020 | 94 | 0.230 |
Why?
|
| Skilled Nursing Facilities | 1 | 2025 | 13 | 0.230 |
Why?
|
| Kidney Diseases | 2 | 2019 | 243 | 0.230 |
Why?
|
| Hispanic Americans | 6 | 2013 | 772 | 0.230 |
Why?
|
| Home Care Services | 1 | 2025 | 51 | 0.220 |
Why?
|
| Cross-Sectional Studies | 7 | 2020 | 1479 | 0.220 |
Why?
|
| Proportional Hazards Models | 7 | 2025 | 773 | 0.220 |
Why?
|
| Alleles | 4 | 2015 | 250 | 0.210 |
Why?
|
| Brain | 4 | 2021 | 965 | 0.210 |
Why?
|
| HIV-1 | 3 | 2015 | 46 | 0.210 |
Why?
|
| Incidence | 4 | 2022 | 1241 | 0.210 |
Why?
|
| England | 1 | 2024 | 4 | 0.210 |
Why?
|
| State Medicine | 1 | 2024 | 4 | 0.210 |
Why?
|
| Algorithms | 3 | 2024 | 536 | 0.210 |
Why?
|
| Critical Illness | 1 | 2024 | 87 | 0.210 |
Why?
|
| Primary Prevention | 1 | 2024 | 55 | 0.200 |
Why?
|
| Apolipoproteins | 2 | 2016 | 194 | 0.200 |
Why?
|
| HIV Infections | 3 | 2015 | 450 | 0.200 |
Why?
|
| Hospitalization | 3 | 2023 | 475 | 0.200 |
Why?
|
| Heart Failure | 2 | 2023 | 728 | 0.200 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 250 | 0.190 |
Why?
|
| Regression Analysis | 2 | 2016 | 273 | 0.190 |
Why?
|
| Cerebrovascular Circulation | 3 | 2022 | 93 | 0.180 |
Why?
|
| Health Status Indicators | 2 | 2016 | 69 | 0.180 |
Why?
|
| Breast Neoplasms | 2 | 2025 | 762 | 0.180 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2022 | 22 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2015 | 821 | 0.180 |
Why?
|
| Homebound Persons | 1 | 2021 | 9 | 0.180 |
Why?
|
| Dental Care | 3 | 2011 | 16 | 0.180 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2022 | 63 | 0.180 |
Why?
|
| Survival Analysis | 2 | 2019 | 477 | 0.170 |
Why?
|
| Health Surveys | 2 | 2019 | 175 | 0.170 |
Why?
|
| Carotid Artery Diseases | 2 | 2014 | 126 | 0.170 |
Why?
|
| European Continental Ancestry Group | 7 | 2014 | 1076 | 0.170 |
Why?
|
| Immunoglobulin G | 2 | 2012 | 129 | 0.170 |
Why?
|
| Sample Size | 2 | 2012 | 38 | 0.170 |
Why?
|
| Sex Factors | 3 | 2019 | 655 | 0.170 |
Why?
|
| Body Height | 2 | 2011 | 34 | 0.160 |
Why?
|
| Diet Therapy | 1 | 2020 | 17 | 0.160 |
Why?
|
| Bicarbonates | 1 | 2020 | 11 | 0.160 |
Why?
|
| Cystatin C | 1 | 2020 | 33 | 0.160 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 280 | 0.160 |
Why?
|
| Genetic Variation | 4 | 2019 | 248 | 0.160 |
Why?
|
| Advance Care Planning | 1 | 2019 | 15 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2020 | 122 | 0.150 |
Why?
|
| Documentation | 1 | 2019 | 39 | 0.150 |
Why?
|
| Infant | 6 | 2013 | 1010 | 0.140 |
Why?
|
| Exercise Therapy | 1 | 2020 | 250 | 0.140 |
Why?
|
| Genotype | 4 | 2015 | 702 | 0.140 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 245 | 0.140 |
Why?
|
| Data Collection | 1 | 2018 | 171 | 0.140 |
Why?
|
| Diet | 3 | 2020 | 383 | 0.140 |
Why?
|
| Dental Care for Children | 2 | 2009 | 4 | 0.140 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 75 | 0.140 |
Why?
|
| Decision Making | 1 | 2019 | 189 | 0.130 |
Why?
|
| Syncope | 1 | 2018 | 25 | 0.130 |
Why?
|
| Retirement | 1 | 2017 | 13 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 38 | 0.130 |
Why?
|
| Vasodilation | 2 | 2016 | 92 | 0.130 |
Why?
|
| Linkage Disequilibrium | 2 | 2015 | 181 | 0.130 |
Why?
|
| Mass Screening | 1 | 2019 | 256 | 0.130 |
Why?
|
| Menopause | 2 | 2015 | 109 | 0.130 |
Why?
|
| Lipoproteins | 1 | 2017 | 95 | 0.120 |
Why?
|
| Computer Simulation | 2 | 2025 | 251 | 0.120 |
Why?
|
| Tilt-Table Test | 1 | 2015 | 13 | 0.120 |
Why?
|
| Postural Balance | 1 | 2017 | 142 | 0.120 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 1 | 2015 | 9 | 0.120 |
Why?
|
| Allostasis | 1 | 2015 | 12 | 0.120 |
Why?
|
| Vasoconstriction | 1 | 2016 | 42 | 0.120 |
Why?
|
| Temporal Lobe | 1 | 2015 | 34 | 0.120 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2015 | 3 | 0.120 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 180 | 0.110 |
Why?
|
| Genetics, Population | 2 | 2012 | 31 | 0.110 |
Why?
|
| Claudins | 1 | 2015 | 8 | 0.110 |
Why?
|
| Gene Regulatory Networks | 2 | 2012 | 45 | 0.110 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2015 | 19 | 0.110 |
Why?
|
| Oxygen | 1 | 2016 | 138 | 0.110 |
Why?
|
| Interleukins | 1 | 2015 | 17 | 0.110 |
Why?
|
| Anthrax | 2 | 2013 | 3 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 37 | 0.110 |
Why?
|
| Young Adult | 8 | 2015 | 2648 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 61 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 72 | 0.110 |
Why?
|
| DNA Copy Number Variations | 2 | 2011 | 11 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 381 | 0.110 |
Why?
|
| Adiponectin | 1 | 2015 | 94 | 0.110 |
Why?
|
| Prediabetic State | 1 | 2015 | 76 | 0.110 |
Why?
|
| Body Weight | 2 | 2020 | 323 | 0.110 |
Why?
|
| Vitamin D | 1 | 2015 | 186 | 0.110 |
Why?
|
| Major Histocompatibility Complex | 1 | 2014 | 17 | 0.110 |
Why?
|
| Physical Fitness | 1 | 2015 | 120 | 0.110 |
Why?
|
| Information Storage and Retrieval | 1 | 2014 | 26 | 0.100 |
Why?
|
| Social Class | 3 | 2009 | 90 | 0.100 |
Why?
|
| Physicians' Offices | 2 | 2011 | 9 | 0.100 |
Why?
|
| Phenotype | 3 | 2011 | 621 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2017 | 355 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 757 | 0.100 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2014 | 12 | 0.100 |
Why?
|
| Models, Statistical | 2 | 2012 | 187 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 203 | 0.100 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2014 | 33 | 0.100 |
Why?
|
| Diabetic Retinopathy | 1 | 2014 | 72 | 0.100 |
Why?
|
| Indoles | 1 | 2014 | 65 | 0.100 |
Why?
|
| Dentists | 2 | 2011 | 2 | 0.100 |
Why?
|
| Diabetic Angiopathies | 1 | 2014 | 150 | 0.100 |
Why?
|
| Heart Rate | 1 | 2015 | 362 | 0.100 |
Why?
|
| Appendicitis | 1 | 2013 | 15 | 0.100 |
Why?
|
| Appendectomy | 1 | 2013 | 19 | 0.100 |
Why?
|
| Medically Underserved Area | 2 | 2011 | 17 | 0.100 |
Why?
|
| Bacillus anthracis | 1 | 2013 | 8 | 0.100 |
Why?
|
| Immunity, Cellular | 1 | 2013 | 21 | 0.100 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 48 | 0.100 |
Why?
|
| Adiposity | 3 | 2025 | 190 | 0.100 |
Why?
|
| Disease Progression | 2 | 2025 | 591 | 0.100 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2014 | 157 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2026 | 110 | 0.100 |
Why?
|
| Diabetic Nephropathies | 1 | 2014 | 223 | 0.090 |
Why?
|
| Pregnancy | 1 | 2015 | 961 | 0.090 |
Why?
|
| Calcifediol | 1 | 2012 | 10 | 0.090 |
Why?
|
| Bipolar Disorder | 1 | 2012 | 14 | 0.090 |
Why?
|
| Estrogens | 1 | 2014 | 194 | 0.090 |
Why?
|
| Risk | 3 | 2020 | 305 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2012 | 28 | 0.090 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2012 | 3 | 0.090 |
Why?
|
| Cadherins | 1 | 2012 | 28 | 0.090 |
Why?
|
| Curriculum | 1 | 2014 | 203 | 0.090 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 43 | 0.090 |
Why?
|
| Students, Medical | 1 | 2014 | 126 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 556 | 0.090 |
Why?
|
| Depression | 1 | 2015 | 420 | 0.090 |
Why?
|
| Health Policy | 2 | 2010 | 89 | 0.090 |
Why?
|
| Antibodies, Bacterial | 1 | 2012 | 34 | 0.090 |
Why?
|
| Animals | 7 | 2015 | 8199 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 181 | 0.090 |
Why?
|
| Receptors, Interleukin | 1 | 2011 | 16 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 67 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 637 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2011 | 46 | 0.090 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2011 | 47 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2011 | 45 | 0.080 |
Why?
|
| Atherosclerosis | 1 | 2017 | 820 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 149 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2011 | 211 | 0.080 |
Why?
|
| Longevity | 1 | 2010 | 23 | 0.080 |
Why?
|
| Genome, Human | 1 | 2011 | 130 | 0.080 |
Why?
|
| Smallpox Vaccine | 1 | 2010 | 6 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2016 | 2316 | 0.080 |
Why?
|
| Counseling | 2 | 2020 | 93 | 0.080 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2010 | 21 | 0.080 |
Why?
|
| Ultrasonography | 2 | 2009 | 393 | 0.080 |
Why?
|
| Research Design | 1 | 2012 | 314 | 0.080 |
Why?
|
| Calcium | 1 | 2012 | 339 | 0.080 |
Why?
|
| Birds | 1 | 2009 | 3 | 0.080 |
Why?
|
| Fee-for-Service Plans | 1 | 2010 | 14 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2011 | 267 | 0.080 |
Why?
|
| Female Athlete Triad Syndrome | 1 | 2009 | 1 | 0.080 |
Why?
|
| Managed Care Programs | 1 | 2010 | 43 | 0.080 |
Why?
|
| Indians, North American | 1 | 2010 | 75 | 0.080 |
Why?
|
| Cause of Death | 3 | 2016 | 236 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2026 | 565 | 0.080 |
Why?
|
| Cariostatic Agents | 1 | 2009 | 4 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2010 | 66 | 0.070 |
Why?
|
| Urban Population | 1 | 2010 | 91 | 0.070 |
Why?
|
| Athletes | 1 | 2009 | 62 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2010 | 178 | 0.070 |
Why?
|
| Language | 1 | 2009 | 36 | 0.070 |
Why?
|
| Hypopharynx | 1 | 2008 | 2 | 0.070 |
Why?
|
| Mucins | 1 | 2008 | 16 | 0.070 |
Why?
|
| Larynx | 1 | 2008 | 17 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2011 | 458 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2012 | 854 | 0.070 |
Why?
|
| Gastroesophageal Reflux | 1 | 2008 | 20 | 0.070 |
Why?
|
| Office Visits | 1 | 2008 | 72 | 0.070 |
Why?
|
| Orthodontics, Corrective | 1 | 2008 | 1 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2025 | 341 | 0.070 |
Why?
|
| Bone Density | 1 | 2009 | 169 | 0.070 |
Why?
|
| Rural Population | 1 | 2010 | 216 | 0.070 |
Why?
|
| Health Personnel | 1 | 2009 | 112 | 0.070 |
Why?
|
| Amenorrhea | 1 | 2007 | 4 | 0.070 |
Why?
|
| Running | 1 | 2007 | 20 | 0.070 |
Why?
|
| Pain | 1 | 2010 | 303 | 0.070 |
Why?
|
| Tissue Survival | 1 | 2007 | 13 | 0.060 |
Why?
|
| Organ Size | 2 | 2019 | 221 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2007 | 72 | 0.060 |
Why?
|
| Orthodontics | 1 | 2007 | 1 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 907 | 0.060 |
Why?
|
| Malocclusion | 1 | 2007 | 5 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 883 | 0.060 |
Why?
|
| Oxygenases | 1 | 2006 | 3 | 0.060 |
Why?
|
| Age Distribution | 3 | 2016 | 194 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 155 | 0.060 |
Why?
|
| Basal Metabolism | 1 | 2026 | 5 | 0.060 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 101 | 0.060 |
Why?
|
| Echocardiography | 1 | 2007 | 190 | 0.060 |
Why?
|
| Myocardium | 1 | 2007 | 184 | 0.060 |
Why?
|
| Thrombospondin 1 | 1 | 2005 | 7 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2005 | 41 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2015 | 146 | 0.060 |
Why?
|
| Health Expenditures | 2 | 2020 | 66 | 0.060 |
Why?
|
| SEER Program | 1 | 2025 | 38 | 0.060 |
Why?
|
| Comparative Effectiveness Research | 1 | 2025 | 28 | 0.060 |
Why?
|
| California | 1 | 2025 | 61 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2025 | 116 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2025 | 187 | 0.050 |
Why?
|
| Exercise | 2 | 2020 | 603 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2024 | 121 | 0.050 |
Why?
|
| Electronics | 1 | 2023 | 15 | 0.050 |
Why?
|
| Genetic Loci | 2 | 2015 | 143 | 0.050 |
Why?
|
| Internationality | 1 | 2023 | 22 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 219 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2023 | 25 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2025 | 252 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2023 | 161 | 0.050 |
Why?
|
| Motor Activity | 2 | 2015 | 332 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 312 | 0.040 |
Why?
|
| Waist Circumference | 2 | 2012 | 91 | 0.040 |
Why?
|
| Kidney Tubules | 1 | 2021 | 25 | 0.040 |
Why?
|
| Lipids | 1 | 2023 | 253 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 133 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 423 | 0.040 |
Why?
|
| Program Evaluation | 2 | 2014 | 171 | 0.040 |
Why?
|
| Independent Living | 1 | 2021 | 90 | 0.040 |
Why?
|
| Medicare Part A | 1 | 2020 | 5 | 0.040 |
Why?
|
| North Carolina | 1 | 2024 | 1300 | 0.040 |
Why?
|
| Medicare Part B | 1 | 2020 | 5 | 0.040 |
Why?
|
| Medicare Part D | 1 | 2020 | 10 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2020 | 18 | 0.040 |
Why?
|
| Nutrition Surveys | 2 | 2011 | 144 | 0.040 |
Why?
|
| Health Services | 1 | 2020 | 40 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 71 | 0.040 |
Why?
|
| Time Factors | 2 | 2016 | 2204 | 0.040 |
Why?
|
| Terminal Care | 1 | 2019 | 25 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2020 | 242 | 0.040 |
Why?
|
| Albuminuria | 1 | 2020 | 172 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 388 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2010 | 174 | 0.040 |
Why?
|
| Gender Identity | 1 | 2018 | 28 | 0.040 |
Why?
|
| Patient Participation | 1 | 2019 | 90 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2019 | 55 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2019 | 413 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 893 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2018 | 90 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2018 | 130 | 0.030 |
Why?
|
| Nomograms | 1 | 2017 | 35 | 0.030 |
Why?
|
| Death | 1 | 2017 | 51 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 183 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 83 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2016 | 22 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 292 | 0.030 |
Why?
|
| Logistic Models | 2 | 2009 | 743 | 0.030 |
Why?
|
| Exercise Test | 1 | 2017 | 217 | 0.030 |
Why?
|
| Animal Feed | 1 | 2015 | 23 | 0.030 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2015 | 10 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 395 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 231 | 0.030 |
Why?
|
| Rest | 1 | 2016 | 48 | 0.030 |
Why?
|
| Posture | 1 | 2015 | 62 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2017 | 160 | 0.030 |
Why?
|
| Baroreflex | 1 | 2015 | 86 | 0.030 |
Why?
|
| Diet, Reducing | 1 | 2015 | 85 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 245 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2016 | 139 | 0.030 |
Why?
|
| Weight Gain | 1 | 2015 | 104 | 0.030 |
Why?
|
| Rats | 2 | 2010 | 1895 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 285 | 0.030 |
Why?
|
| Computational Biology | 1 | 2015 | 99 | 0.030 |
Why?
|
| Librarians | 1 | 2014 | 3 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2015 | 188 | 0.030 |
Why?
|
| Africa | 1 | 2014 | 26 | 0.030 |
Why?
|
| Models, Biological | 1 | 2016 | 408 | 0.030 |
Why?
|
| Basilar Artery | 1 | 2014 | 9 | 0.030 |
Why?
|
| Viral Load | 1 | 2014 | 73 | 0.030 |
Why?
|
| Problem-Based Learning | 1 | 2014 | 29 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 553 | 0.030 |
Why?
|
| Diet, Atherogenic | 1 | 2014 | 74 | 0.030 |
Why?
|
| Haplorhini | 1 | 2014 | 75 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 555 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 101 | 0.030 |
Why?
|
| Carotid Artery, Internal | 1 | 2014 | 33 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 2015 | 338 | 0.030 |
Why?
|
| HLA-A Antigens | 1 | 2013 | 2 | 0.020 |
Why?
|
| Homozygote | 1 | 2013 | 52 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 25 | 0.020 |
Why?
|
| Random Allocation | 1 | 2014 | 247 | 0.020 |
Why?
|
| Heterozygote | 1 | 2013 | 60 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2013 | 55 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 368 | 0.020 |
Why?
|
| Acute Disease | 1 | 2013 | 253 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 94 | 0.020 |
Why?
|
| Obesity, Abdominal | 1 | 2012 | 24 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 179 | 0.020 |
Why?
|
| OX40 Ligand | 1 | 2011 | 6 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2011 | 8 | 0.020 |
Why?
|
| Vitamins | 1 | 2012 | 71 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2012 | 63 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 188 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 2011 | 24 | 0.020 |
Why?
|
| Alberta | 1 | 2011 | 1 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 36 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2011 | 31 | 0.020 |
Why?
|
| Vaccination | 1 | 2013 | 156 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 425 | 0.020 |
Why?
|
| Tooth Diseases | 1 | 2011 | 6 | 0.020 |
Why?
|
| Urban Health | 1 | 2011 | 14 | 0.020 |
Why?
|
| Periodontal Diseases | 1 | 2011 | 17 | 0.020 |
Why?
|
| Self Concept | 1 | 2011 | 45 | 0.020 |
Why?
|
| Fasting | 1 | 2011 | 88 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 717 | 0.020 |
Why?
|
| Rural Health | 1 | 2011 | 22 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2013 | 666 | 0.020 |
Why?
|
| Mouth Diseases | 1 | 2011 | 21 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 603 | 0.020 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2010 | 1 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 235 | 0.020 |
Why?
|
| Genes | 1 | 2010 | 13 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2010 | 12 | 0.020 |
Why?
|
| Poverty | 1 | 2011 | 105 | 0.020 |
Why?
|
| Markov Chains | 1 | 2010 | 31 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 1534 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 32 | 0.020 |
Why?
|
| Midwestern United States | 1 | 2009 | 8 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 565 | 0.020 |
Why?
|
| Communication Barriers | 1 | 2009 | 18 | 0.020 |
Why?
|
| Energy Intake | 1 | 2009 | 122 | 0.020 |
Why?
|
| Pepsin A | 1 | 2008 | 5 | 0.020 |
Why?
|
| Epithelium | 1 | 2008 | 22 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2008 | 69 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 316 | 0.020 |
Why?
|
| Income | 1 | 2009 | 66 | 0.020 |
Why?
|
| Minority Groups | 1 | 2009 | 81 | 0.020 |
Why?
|
| Educational Status | 1 | 2009 | 167 | 0.020 |
Why?
|
| Marital Status | 1 | 2008 | 21 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2008 | 131 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 246 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2007 | 20 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 85 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2008 | 228 | 0.020 |
Why?
|
| Gene Expression | 1 | 2008 | 345 | 0.020 |
Why?
|
| Dental Health Surveys | 1 | 2007 | 1 | 0.020 |
Why?
|
| Insurance, Dental | 1 | 2007 | 2 | 0.020 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2007 | 19 | 0.020 |
Why?
|
| Oral Health | 1 | 2007 | 20 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2007 | 94 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2007 | 194 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 499 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2007 | 154 | 0.020 |
Why?
|
| Kinetics | 1 | 2006 | 250 | 0.020 |
Why?
|
| Nystatin | 1 | 2005 | 2 | 0.010 |
Why?
|
| Erythrocyte Membrane | 1 | 2005 | 2 | 0.010 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2005 | 3 | 0.010 |
Why?
|
| Osmosis | 1 | 2005 | 4 | 0.010 |
Why?
|
| Dehydration | 1 | 2005 | 8 | 0.010 |
Why?
|
| Sucrose | 1 | 2005 | 19 | 0.010 |
Why?
|
| Women's Health | 1 | 2007 | 230 | 0.010 |
Why?
|
| Capillaries | 1 | 2005 | 25 | 0.010 |
Why?
|
| Phosphatidylserines | 1 | 2005 | 9 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2005 | 100 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 183 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 897 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 839 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 1083 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 521 | 0.010 |
Why?
|
| Mice | 1 | 2005 | 2571 | 0.010 |
Why?
|